– Growing counterfeit cigarette manufacture and distribution leads to severe negative consequences for national credibility and regional economy
SEOUL, South Korea, June 2, 2025 /PRNewswire/ — KT&G, a global tobacco company, stated on the 2nd that it has taken civil legal action against local entities for manufacturing and distributing counterfeit products under its global superslim brand “ESSE.”
KT&G has recently confirmed that counterfeiters used aliases such as “KT&G India”, “KT&G Punjab”, and “KT&G Ambala” to illegally manufacture and distribute a significant volume of counterfeit cigarettes, appropriating the company’s global superslim brand “ESSE.”
To prevent counterfeiting activities, KT&G has taken legal action against local manufacturers and distributors across India, emphasizing that the company is unrelated to “KT&G India”, “KT&G Punjab”, and “KT&G Ambala” in any way.
Recently, the manufacture and distribution of counterfeit products under globally renowned brands are rapidly growing, gravely impacting national economy and regional societies. As the eradication of counterfeit tobacco becomes an urgent task, KT&G as well as other global tobacco manufacturers are heightening their responses.
Alongside legal actions, KT&G also plans an official brand launch in the Indian market on June 2nd. Any inquiries, including tips on counterfeit products or questions regarding official sale points or imports are handled by the local Indian partner, Kedara (e-mail: info@kedaratrading.com).
The manufacturer of the global brand ESSE, KT&G, is a well-known Korean company. It holds dominant positions in many markets, including the health functional foods market. It is also a global company that sells 870 brands across 148 countries as of 2024.
Logo – https://mma.prnewswire.com/media/2316472/KT_G_Logo.jpg
View original content:https://www.prnewswire.com/in/news-releases/ktg-takes-legal-action-against-local-counterfeit-cigarette-manufacturers-and-distributors-in-india-302470246.html
Sustained Worldwide Outreach Drives Greater Collaboration OpportunitiesBEIJING, Dec. 7, 2025 /PRNewswire/ -- The 4th China…
All three dose groups (50 mg, 100 mg and 200 mg) showed impressive monotherapy efficacy,…
93% overall response and 76% complete response rates with median progression-free survival of 18 months…
December 07, 2025 16:00 ET | Source: Wave Life Sciences USA, Inc. CAMBRIDGE, Mass., Dec.…
New York, NY, Dec. 06, 2025 (GLOBE NEWSWIRE) -- RadiantVibe Capital Consortium today announced the…
New York, USA, Dec. 06, 2025 (GLOBE NEWSWIRE) -- BI DeFi has officially launched its…